Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lishatoclax plus decitabine in venetoclax-failed myelodysplastic neoplasms
ChiCTR2600125359Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lishatoclax and decitabine in myelodysplastic syndrome (MDS), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Overall remission rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
lishatoclaxdecitabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2600125359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125359.